spacer
home > pmps > spring 2018 > air purity
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Air Purity

As the UK’s pharmaceutical sector continues to grow, so too does the demand for large volumes of highquality compressed air for powering manufacturing processes. Air purity is essential when meeting strict hygiene regulations, designed to prevent process and product contamination. Oil-free technologies can be instrumental in delivering the required air purity, and oil-free compressors can even help deliver improved efficiencies for factory owners and operators.

Often referred to as the ‘fourth utility’, compressed air is pivotal to the pharma manufacturing industry. A reliable supply of compressed air is absolutely vital to a wide variety of applications across the pharma sector. However, because this compressed air comes into direct contact with pharmaceutical products during the manufacturing process, it is of paramount importance that it is of exceptionally high quality.

Even the smallest risk of contamination can have a serious effect on tools such as air curtains, control valves, and cylinders, as well as material handling, process air, and product drying. Such consequences can often only be resolved at significant expense, saddling pharma factory owners and operators with unnecessary costs that could impact their bottom line.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Richard Hilton is the Product Director for Gardner Denver, which delivers a broad range of compressor and vacuum products in a wide array of technologies to end-user and original equipment manufacturer customers to varied sectors worldwide. He is a 28-year veteran of the compressed air industry and has worked across Gardner Denver’s brand portfolio for almost 20 years. Richard is currently responsible for the group’s industrial compressor product groups across Europe, the Middle East, and Asia.
spacer
Richard Hilton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging

Philadelphia, USA – September 10, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce the acquisition of San Diego-based Sherpa Clinical Packaging (Sherpa), which expands PCI’s U.S. operations to the West Coast. The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. The addition of Sherpa’s capabilities also enables PCI to better support customers from early phases of clinical development through to commercial launch.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

10th Annual NGS & Clinical Diagnostics Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 10thAnnual NGS & Clinical Diagnostics Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement